{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:41:20Z","timestamp":1787989280441,"version":"build-2784847793"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T00:00:00Z","timestamp":1601769600000},"content-version":"vor","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["405231\/2015-6"],"award-info":[{"award-number":["405231\/2015-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001688","name":"International Centre for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019125","name":"Sorbonne Universit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.antiviral.2019.104615","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T11:59:42Z","timestamp":1569844782000},"page":"104615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation"],"prefix":"10.1016","volume":"172","author":[{"given":"Marcos P.","family":"Thom\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Borde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette K.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao A.P.","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre E.","family":"Escargueil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mar\u00e9chal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.104615_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0030404","article-title":"Epstein-barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis","volume":"3","author":"Altmann","year":"2005","journal-title":"PLoS Biol."},{"key":"10.1016\/j.antiviral.2019.104615_bib2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/molecules24050997","article-title":"Novel therapeutics for epstein\u2013barr virus","volume":"24","author":"Andrei","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2019.104615_bib3","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.4049\/jimmunol.158.9.4045","article-title":"Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines","volume":"158","author":"Beatty","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2019.104615_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15257770.2016.1210805","article-title":"Equilibrative nucleoside transporters - a review","volume":"36","author":"Boswell-Casteel","year":"2017","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2019.104615_bib5","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.3390\/v7062747","article-title":"Dynamics of virus-receptor interactions in virus binding, signaling, and endocytosis","volume":"7","author":"Boulant","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.104615_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.vph.2007.12.004","article-title":"Dipyridamole, cerebrovascular disease, and the vasculature","volume":"48","author":"Chakrabarti","year":"2008","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.104615_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-virology-110615-042358","article-title":"Epstein-barr virus: the path from latent to productive infection","volume":"3","author":"Chiu","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.antiviral.2019.104615_bib8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2174\/1568026615666150220111942","article-title":"Dipyridamole: a drug with unrecognized antioxidant activity","volume":"15","author":"Ciacciarelli","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.104615_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104615_bib10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2019.104615_bib11","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.3012779","article-title":"Calcium modulation activates Epstein-Barr virus genome in latently infected cells","volume":"232","author":"Faggioni","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.104615_bib12","doi-asserted-by":"crossref","first-page":"11062","DOI":"10.1128\/JVI.79.17.11062-11070.2005","article-title":"Dipyridamole reversibly inhibits Mengovirus RNA replication","volume":"79","author":"Fata-Hartley","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104615_bib13","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/emboj\/19.12.3080","article-title":"The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators","volume":"19","author":"Feederle","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2019.104615_bib14","doi-asserted-by":"crossref","first-page":"11798","DOI":"10.1128\/JVI.78.21.11798-11806.2004","article-title":"Inhibition of epstein-barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells","volume":"78","author":"Gao","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104615_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0163-7258(89)90084-3","article-title":"Enhancement of 5-fluorouracil\u2019s anticancer activity by dipyridamole","volume":"40","author":"Grem","year":"1989","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2019.104615_bib16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.104615_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nm0197-89","article-title":"Cloning of a human nucleoside transporter implicated in the Cellular uptake of adenosine and chemotherapeutic drugs","volume":"3","author":"Griffiths","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2019.104615_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0049-3848(83)90356-0","article-title":"Mechanism of action of dipyridamole","volume":"29","author":"Harker","year":"1983","journal-title":"Thromb. Res."},{"key":"10.1016\/j.antiviral.2019.104615_bib19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/(SICI)1096-9071(199610)50:2<198::AID-JMV15>3.0.CO;2-I","article-title":"Inhibition of herpes simplex virus reactivation by dipyridamole in a mouse model","volume":"50","author":"Hay","year":"1996","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2019.104615_bib20","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/lt.21498","article-title":"Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus","volume":"14","author":"Hierro","year":"2008","journal-title":"Liver Transplant."},{"key":"10.1016\/j.antiviral.2019.104615_bib21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1432-2277.2012.01485.x","article-title":"(Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation","volume":"25","author":"H\u00f6cker","year":"2012","journal-title":"Transpl. Int."},{"key":"10.1016\/j.antiviral.2019.104615_bib22","doi-asserted-by":"crossref","first-page":"13993","DOI":"10.1128\/JVI.79.22.13993-14003.2005","article-title":"Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model","volume":"79","author":"Hong","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104615_bib23","doi-asserted-by":"crossref","first-page":"16242","DOI":"10.1073\/pnas.1418974111","article-title":"Epstein\u2013Barr virus replicating in epithelial cells","volume":"111","author":"Hutt-Fletcher","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.antiviral.2019.104615_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2016.01602","article-title":"Epstein\u2013barr virus: diseases linked to infection and transformation","volume":"7","author":"Jha","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2019.104615_bib25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcv.2006.06.013","article-title":"Hypoxia can contribute to the induction of the Epstein-Barr virus (EBV) lytic cycle","volume":"37","author":"Jiang","year":"2006","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"10.1016\/j.antiviral.2019.104615_bib26","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/ijc.22839","article-title":"Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease","volume":"121","author":"Jones","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.antiviral.2019.104615_bib27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semcancer.2014.01.002","article-title":"Regulation of the latent-lytic switch in Epstein-Barr virus","volume":"26","author":"Kenney","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.antiviral.2019.104615_bib28","first-page":"H804","article-title":"Effects of dipyridamole on myocardial adenosine and active hyperemia","volume":"247","author":"Knabb","year":"1984","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.antiviral.2019.104615_bib29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1128\/JVI.78.1.104-115.2004","article-title":"Inhibition of S-phase cyclin-dependent kinase activity blocks expression of epstein-barr virus immediate-early and early genes, preventing viral lytic replication","volume":"78","author":"Kudoh","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104615_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0960327110368696","article-title":"Toxicokinetics of a dipyridamole (Persantin) intoxication: case report","volume":"30","author":"Lagas","year":"2011","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.antiviral.2019.104615_bib31","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.7150\/ijbs.16564","article-title":"Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis","volume":"12","author":"Li","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.antiviral.2019.104615_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115790","article-title":"A multifunctional drug combination shows highly potent therapeutic efficacy against human cancer xenografts in athymic mice","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.104615_bib33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0042-6822(79)90455-0","article-title":"Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate","volume":"94","author":"Luka","year":"1979","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.104615_bib34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1128\/JVI.01512-10","article-title":"A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas","volume":"85","author":"Ma","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104615_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1053-2498(01)00407-7","article-title":"Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients","volume":"21","author":"Malouf","year":"2002","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.antiviral.2019.104615_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coviro.2018.08.014","article-title":"Contribution of the KSHV and EBV lytic cycles to tumourigenesis","volume":"32","author":"Manners","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2019.104615_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00975-17","article-title":"Epstein-barr virus BKRF4 gene product is required for efficient progeny production","volume":"91","author":"Masud","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104615_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1476-4598-8-18","article-title":"Inhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds","volume":"8","author":"Matusali","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.antiviral.2019.104615_bib39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/1348-0421.12155","article-title":"Regulation of Epstein-Barr virus reactivation from latency","volume":"58","author":"Murata","year":"2014","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2019.104615_bib40","series-title":"ELS","article-title":"Nucleotide synthesis via salvage pathway","author":"Nyhan","year":"2014"},{"key":"10.1016\/j.antiviral.2019.104615_bib41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/cancers10060197","article-title":"Antiviral drugs for EBV","volume":"10","author":"Pagano","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.antiviral.2019.104615_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virusres.2004.11.005","article-title":"Cell entry and export of nucleoside analogues","volume":"107","author":"Pastor-Anglada","year":"2005","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2019.104615_bib43","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1128\/AAC.35.6.1250","article-title":"Differential inhibition of 2\u2019-deoxycytidine salvage as a possible mechanism for potentiation of the anti-human immunodeficiency virus activity of 2\u2019,3\u2019-dideoxycytidine by dipyridamole","volume":"35","author":"Patel","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104615_bib44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.antiviral.2013.04.008","article-title":"Development of cellular signaling pathway inhibitors as new antivirals against influenza","volume":"98","author":"Planz","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104615_bib45","article-title":"Drug repurposing: progress, challenges and recommendations","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2019.104615_bib46","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/ijc.2910570623","article-title":"Endogenous TGF-\u03b2 contributes to the induction of the EBV lytic cycle in two burkitt lymphoma cell lines","volume":"57","author":"Renzo","year":"1994","journal-title":"Int. J. Cancer"},{"issue":"480","key":"10.1016\/j.antiviral.2019.104615_bib47","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.virol.2015.02.038","article-title":"Viral activation of cellular metabolism","volume":"479","author":"Sanchez","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.104615_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41426-018-0023-3","article-title":"Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for the treatment of influenza in hospitalized patients","volume":"7","author":"Scheuch","year":"2018","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.antiviral.2019.104615_bib49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10585-012-9506-0","article-title":"Dipyridamole prevents triple-negative breast-cancer progression","volume":"30","author":"Spano","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.antiviral.2019.104615_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ijc.2910330106","article-title":"Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines","volume":"33","author":"Takada","year":"1984","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.antiviral.2019.104615_bib51","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1128\/AAC.45.12.3657-3659.2001","article-title":"Inhibition of herpes simplex virus reactivation by dipyridamole","volume":"45","author":"Tenser","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104615_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.06.001","article-title":"Dipyridamole impairs autophagic flux and exerts antiproliferative activity on prostate cancer cells","author":"Thom\u00e9","year":"2019","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.antiviral.2019.104615_bib53","first-page":"484","article-title":"Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study","volume":"31","author":"Ville","year":"2018","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ Transplant."},{"key":"10.1016\/j.antiviral.2019.104615_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2013.08.063","article-title":"Dipyridamole analogues as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4)","volume":"86","author":"Wang","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.104615_bib55","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/cancers10040120","article-title":"Perspective: contribution of epstein\u2013barr virus (EBV) reactivation to the carcinogenicity of nasopharyngeal cancer cells","volume":"10","author":"Wu","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.antiviral.2019.104615_bib56","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jmv.21165","article-title":"Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir","volume":"80","author":"Yoshizaki","year":"2008","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2019.104615_bib57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/272373a0","article-title":"Persisting oncogenic herpesvirus induced by the tumour promotor TPA","volume":"272","author":"zur Hausen","year":"1978","journal-title":"Nature"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219303304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219303304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:11:32Z","timestamp":1777497092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219303304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":57,"alternative-id":["S0166354219303304"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104615","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104615"}}